USPTO published patent application US20260092263A1 disclosing amino acid sequences for modified, truncated forms of human GlcNAc-1-Phosphotransferase. The disclosed sequences retain phosphotransferase activity and the ability to phosphorylate target proteins, whether lysosomal or non-lysosomal. Truncated PTase forms with modified or absent linkers and lacking the C-terminal transmembrane and cytosolic domain are demonstrated to retain functional activity. Inventors are Lin Liu and Andrew Charles Hedman.

This is an informational patent application publication with no compliance deadlines or regulatory requirements. Entities conducting research in enzyme engineering, lysosomal targeting, or protein phosphorylation should review the application claims to assess potential freedom-to-operate implications or licensing opportunities. The CPC classifications (C12N 9/1288, C12Y 207/07049) indicate relevance to biocatalytic enzyme technologies.